Share on StockTwits

Edap Tms SA (NASDAQ:EDAP) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Tuesday, AnalystRatings.Net reports.

According to Zacks, “EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. “

Separately, HC Wainwright reiterated a “buy” rating and issued a $4.50 price target on shares of Edap Tms SA in a research report on Tuesday, July 21st.

Shares of Edap Tms SA (NASDAQ:EDAP) traded down 0.54% during midday trading on Tuesday, hitting $5.52. 258,056 shares of the company were exchanged. Edap Tms SA has a one year low of $1.47 and a one year high of $6.57. The company’s 50 day moving average price is $4.81 and its 200 day moving average price is $3.89. The firm has a market cap of $137.77 million and a P/E ratio of 64.94.

Edap Tms SA (NASDAQ:EDAP) last released its quarterly earnings data on Wednesday, August 26th. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.07. The firm had revenue of $8.70 million for the quarter, compared to the consensus estimate of $7.58 million. Equities analysts expect that Edap Tms SA will post ($0.08) EPS for the current year.

12 Month Chart for NASDAQ:EDAP

EDAP TMS S.A. (NASDAQ:EDAP) is a holding company. The Business is engaged in developing and marketing the Ablatherm and Focal One apparatus for high intensity focused ultrasound (HIFU) treatment of localized prostate cancer. It runs two departments: urology and High Intensity Focused Ultrasound Apparatus and Services (UDS) (including lithotripsy activities). Through those two offices, the business creates, develops and markets medical devices, chiefly for urological disorders. The Company’s HIFU and UDS offices manage in the Americas, Europe, Asia and the remaining whole world. HIFU technology is being developed by it for the treatment of specific other forms of tumors. Additionally, it produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL) and distributes other kinds of urology devices in some specific states. The Company’s subsidiaries include EDAP TMS France SAS, EDAP Technomed Inc., EDAP Technomed Co. Ltd, among others.

Get a free copy of the Zacks research report on Edap Tms SA (EDAP)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Edap Tms SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms SA and related companies with's FREE daily email newsletter.